by The global drug discovery market size is forecasted to reach from US$ 74.96 billion in 2021 to US$ 161.76 billion by 2030 and is anticipated to grow at compounded annual growth rate (CAGR) of 8.9% from 2021 to 2030. The report contains 150+ pages with detailed analysis.
The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2021 to 2030.
The drug discovery market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit). The report offers exclusive insights to help companies make informed decisions to sustain growth through the assessment period.
Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1464
The global drug discovery services market is primarily driven by the increased investments in the research & development activities by the pharmaceutical and biologics companies across the globe. The rising prevalence of various diseases and the growing geriatric population across the globe are the major contributors to the demand for pharmaceutical drugs. As per the United Nations, the geriatric population across the globe is estimated to reach 2 billion by 2050.
The elderly people are more susceptible to chronic diseases and hence spend more on the life-saving drugs. The increased need for the development of new and innovative drugs for the treatment of various common and rare diseases is fueling the demand for the drug discovery services. The patents expiry and growing demand for the biopharmaceutical drugs in the emerging economies is expected to drive the growth of the global drug discovery services market during the forecast period.
Scope of the Drug Discovery Market
| Report Coverage | Details |
| Market Size by 2030 | US$ 161.76 Billion |
| Growth Rate from 2021 to 2030 | CAGR of 8.9% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Segments Covered | Drug Type, End User, Region |
Competitive Intelligence
The report provides an understanding of the market composition and explains the role of established players and regional contributors. It is essential for the market players to make calculative moves and focus on client acquisition and retention. The detailed company profiles will provide the necessary intelligence to the reader. In order to maintain their share, the market players are focusing on strategies such as cross-border expansion, product differentiation and so on.
Some of the prominent players in the global drug discovery market are listed as below:
- Pfizer Inc.
- GlaxoSmithKline PLC
- Merck & Co. Inc.
- Agilent Technologies Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Bayer AG
- Abbott Laboratories Inc.
- AstraZeneca PLC
- Shimadzu Corp
Market Dynamics
Driver
Increasing R & D expenditure by the pharmaceutical companies
According to the International Federation of Pharmaceutical Manufacturers & Associations, the pharmaceutical industry spent around US$150 billion in the research & development activities. It is estimated that on an average, a pharmaceutical company spends around 17% of its revenues on the research & development. Therefore, the rapidly growing pharmaceutical industry and surging investments by them in the R&D is expected to drive the growth of the global drug discovery services market during the forecast period.
Restraint
High costs associated with the drug discovery
A huge cost is involved in the services of drug discovery, owing to the higher attrition rate of the candidates during the development phase. Moreover, the research related to rare diseases requires a specific candidates’ group for the clinical trials. Moreover, the success rate is very low and the number of drugs that receives approval is very low. This involves a huge cost.
Opportunity
Rapidly growing biologics industry
The biologics industry has produced several life-saving innovative drugs that can cure chronic diseases such as cancer, diabetes, and CVDs. The rising awareness regarding the biologics is boosting the demand for the biologics. The biopharmaceuticals alone accounts for 20% of the pharmaceutical industry and is rapidly growing, which offers immense growth opportunities to the market players.
Challenge
Higher attrition rate of the candidates
The most difficult task in the drug discovery services is the identification and retention of the candidates in the clinical trials phase. The higher attrition rate of the candidates is a major challenge for the market players.
Report Highlights
- Based on the drug type, the small molecules segment dominated the market in 2020, owing to its increased demand among the patients. The small molecules can effectively treat the infected cells with low or no side-effects, which makes it a popular drug among the population.
- Based on the type, the medicinal chemistry segment dominated the market in 2020. This is attributable to the increased applications of the medicinal chemistry from pre-clinical trials to the candidate delivery. The rising investments by the pharmaceutical companies in the drug discovery services are boosting the growth of this segment.
- Based on the therapeutic area, the oncology segment dominated the market in 2020. This is attributed to the increased prevalence of cancer among the population. According to the International Agency for Research on Cancer, around 19.3 million new cancer cases and around 10 million cancer deaths were reported in 2020. The new cancer cases are expected to rise by 47% from 2020 to 2040, globally.
Regional Snapshot
In 2020, North America dominated the glob al drug discover services market. The increased prevalence of various chronic diseases in US is a major factor that attracts the investments from the pharmaceutical companies towards the research and drug discovery activities. As peer the CDC, around 92.1 million adults in US are suffering from at least one type of cardiovascular disease. It is estimated that over half of the US population is suffering from at least one chronic disease such as cancer, CVDs, respiratory diseases, and neurological disorders. This results in the increased demand for the new and innovative drugs. Moreover, as per the Population Reference Bureau, the number of people aged 65 years and above is expected to reach at 95 million in US by 2060. The geriatric people has higher demand for the various life-saving drugs as they are more prone to various diseases. The presence of several top pharmaceutical companies in the region results in the increased investments towards the drug discovery activities.
Asia Pacific is estimated to be the most opportunistic market during the forecast period. The rising investments by the top global players in the region owing to the cheap availability of factors of production, availability of several top research companies, and favorable government regulations are collectively driving the growth of the drug discovery services market. The rising geriatric population and rising prevalence of chronic diseases due to various reasons is supplementing the demand for the innovative life-saving drugs, which fuels the investments towards the drug discovery services.
Segments Covered in the Report
By Drug Type
- Small Molecule
- Large Molecule
By End User
- Pharmaceutical Companies
- CROs
- Others
By Technology
- High Throughput Screening
- Pharmacogenomics
- Combinatorial Chemistry
- Nanotechnology
- Other Technologies
Regional Segmentation
– North America (U.S. and Canada)
– Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
– Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
– Latin America (Brazil and Rest of Latin America)
– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Why should you invest in this report?
If you are aiming to enter the global drug discovery market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for drug discovery are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Buy Full Research Report, Click Here@ https://www.precedenceresearch.com/checkout/1464
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Drug Discovery Market
5.1. COVID-19 Landscape: Drug Discovery Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Drug Discovery Market, By End User
8.1. Drug Discovery Market, by End User Type, 2021-2030
8.1.1. Pharmaceutical Companies
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. CROs
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Drug Discovery Market, By Drug Type
9.1. Drug Discovery Market, by Drug Type, 2021-2030
9.1.1. Small Molecule
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Large Molecule
9.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Drug Discovery Market, By Technology
10.1. Drug Discovery Market, by Technology, 2021-2030
10.1.1. High Throughput Screening
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Pharmacogenomics
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Combinatorial Chemistry
10.1.3.1. Market Revenue and Forecast (2019-2030)
10.1.4. Nanotechnology
10.1.4.1. Market Revenue and Forecast (2019-2030)
10.1.5. Other Technologies
10.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Drug Discovery Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by End User (2019-2030)
11.1.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.1.3. Market Revenue and Forecast, by Technology (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by End User (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.1.4.3. Market Revenue and Forecast, by Technology (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by End User (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Technology (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by End User (2019-2030)
11.2.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.3. Market Revenue and Forecast, by Technology (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by End User (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.4.3. Market Revenue and Forecast, by Technology (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by End User (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Technology (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by End User (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Technology (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by End User (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Technology (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by End User (2019-2030)
11.3.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.3. Market Revenue and Forecast, by Technology (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by End User (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.4.3. Market Revenue and Forecast, by Technology (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by End User (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Technology (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by End User (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Technology (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by End User (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Technology (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by End User (2019-2030)
11.4.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.3. Market Revenue and Forecast, by Technology (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by End User (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.4.3. Market Revenue and Forecast, by Technology (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by End User (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Technology (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by End User (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Technology (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by End User (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Technology (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by End User (2019-2030)
11.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5.3. Market Revenue and Forecast, by Technology (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by End User (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5.4.3. Market Revenue and Forecast, by Technology (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by End User (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Technology (2019-2030)
Chapter 12. Company Profiles
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. GlaxoSmithKline PLC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Merck & Co. Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Agilent Technologies Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Eli Lilly and Company
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. F. Hoffmann-La Roche Ltd
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Bayer AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Abbott Laboratories Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AstraZeneca PLC
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Shimadzu Corp
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1464
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
